Severe Psoriasis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 80 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Severe Psoriasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Severe Psoriasis - Pipeline Review, H2 2014', provides an overview of the Severe Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Severe Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Severe Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Severe Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Severe Psoriasis Overview 7
Therapeutics Development 8
Pipeline Products for Severe Psoriasis - Overview 8
Pipeline Products for Severe Psoriasis - Comparative Analysis 9
Severe Psoriasis - Therapeutics under Development by Companies 10
Severe Psoriasis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Severe Psoriasis - Products under Development by Companies 14
Severe Psoriasis - Companies Involved in Therapeutics Development 15
Johnson & Johnson 15
Boehringer Ingelheim GmbH 16
Amgen Inc. 17
Eli Lilly and Company 18
Merck & Co., Inc. 19
ApoPharma Inc. 20
Novartis AG 21
Pfizer Inc. 22
Idera Pharmaceuticals, Inc. 23
Almirall, S.A. 24
Syntrix Biosystems, Inc. 25
Vascular Biogenics Ltd. 26
Severe Psoriasis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
brodalumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ixekizumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
secukinumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
tildrakizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LAS-41008 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
adalimumab biosimilar - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
baricitinib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
VB-201 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
aminopterin sodium - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
orilotimod - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BI-655066 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
IMO-8400 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PF-04965842 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AMG-811 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
guselkumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Severe Psoriasis - Recent Pipeline Updates 59
Severe Psoriasis - Dormant Projects 75
Severe Psoriasis - Discontinued Products 76
Severe Psoriasis - Product Development Milestones 77
Featured News & Press Releases 77
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Number of Products under Development for Severe Psoriasis, H2 2014 8
Number of Products under Development for Severe Psoriasis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Severe Psoriasis - Pipeline by Johnson & Johnson, H2 2014 15
Severe Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 16
Severe Psoriasis - Pipeline by Amgen Inc., H2 2014 17
Severe Psoriasis - Pipeline by Eli Lilly and Company, H2 2014 18
Severe Psoriasis - Pipeline by Merck & Co., Inc., H2 2014 19
Severe Psoriasis - Pipeline by ApoPharma Inc., H2 2014 20
Severe Psoriasis - Pipeline by Novartis AG, H2 2014 21
Severe Psoriasis - Pipeline by Pfizer Inc., H2 2014 22
Severe Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 23
Severe Psoriasis - Pipeline by Almirall, S.A., H2 2014 24
Severe Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2014 25
Severe Psoriasis - Pipeline by Vascular Biogenics Ltd., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Severe Psoriasis Therapeutics - Recent Pipeline Updates, H2 2014 59
Severe Psoriasis - Dormant Projects, H2 2014 75
Severe Psoriasis - Discontinued Products, H2 2014 76